XOLAIR has been shown to significantly reduce exacerbations in appropriate Allergic Asthma patients uncontrolled on inhaled corticosteroids (ICS) 1.

Multiple clinical studies were done to analyze the efficacy and safety of XOLAIR in two patient populations:

  1. Adolescent and adult patients aged ≥12 years. See data.
  2. Pediatric patients aged 6 to <12 years. See data.

See additional information for patient baseline characteristics. Please see full safety information

Adolescent & Adult Study Results (≥12 Years)

Pediatric Study Results (6 to <12 Years)

Patient Baseline Characteristics